JP2021535140A5 - - Google Patents

Info

Publication number
JP2021535140A5
JP2021535140A5 JP2021510639A JP2021510639A JP2021535140A5 JP 2021535140 A5 JP2021535140 A5 JP 2021535140A5 JP 2021510639 A JP2021510639 A JP 2021510639A JP 2021510639 A JP2021510639 A JP 2021510639A JP 2021535140 A5 JP2021535140 A5 JP 2021535140A5
Authority
JP
Japan
Prior art keywords
antibody
naturally
antibody fragment
molecule
amino acid
Prior art date
Application number
JP2021510639A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020047176A5 (https=
JP2021535140A (ja
JP7759805B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048677 external-priority patent/WO2020047176A1/en
Publication of JP2021535140A publication Critical patent/JP2021535140A/ja
Publication of JPWO2020047176A5 publication Critical patent/JPWO2020047176A5/ja
Publication of JP2021535140A5 publication Critical patent/JP2021535140A5/ja
Priority to JP2025050991A priority Critical patent/JP2025098156A/ja
Application granted granted Critical
Publication of JP7759805B2 publication Critical patent/JP7759805B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510639A 2018-08-28 2019-08-28 抗cd3抗体葉酸生物複合体およびその使用 Active JP7759805B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050991A JP2025098156A (ja) 2018-08-28 2025-03-26 抗cd3抗体葉酸生物複合体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723793P 2018-08-28 2018-08-28
US62/723,793 2018-08-28
PCT/US2019/048677 WO2020047176A1 (en) 2018-08-28 2019-08-28 Anti-cd3 antibody folate bioconjugates and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050991A Division JP2025098156A (ja) 2018-08-28 2025-03-26 抗cd3抗体葉酸生物複合体およびその使用

Publications (4)

Publication Number Publication Date
JP2021535140A JP2021535140A (ja) 2021-12-16
JPWO2020047176A5 JPWO2020047176A5 (https=) 2022-09-06
JP2021535140A5 true JP2021535140A5 (https=) 2022-09-06
JP7759805B2 JP7759805B2 (ja) 2025-10-24

Family

ID=68051890

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510639A Active JP7759805B2 (ja) 2018-08-28 2019-08-28 抗cd3抗体葉酸生物複合体およびその使用
JP2025050991A Pending JP2025098156A (ja) 2018-08-28 2025-03-26 抗cd3抗体葉酸生物複合体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050991A Pending JP2025098156A (ja) 2018-08-28 2025-03-26 抗cd3抗体葉酸生物複合体およびその使用

Country Status (12)

Country Link
US (1) US12377294B2 (https=)
EP (1) EP3844188A1 (https=)
JP (2) JP7759805B2 (https=)
KR (1) KR20210063351A (https=)
CN (1) CN111417655A (https=)
AU (1) AU2019327456A1 (https=)
BR (1) BR112021003843A2 (https=)
CA (1) CA3110647A1 (https=)
IL (1) IL281076A (https=)
MX (1) MX2021002301A (https=)
SG (1) SG11202101875VA (https=)
WO (1) WO2020047176A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851488B2 (en) * 2015-11-03 2023-12-26 Ambrx, Inc. Anti-CD3-folate conjugates and their uses
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2021173889A1 (en) * 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12195524B2 (en) 2020-08-25 2025-01-14 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
JP2025535713A (ja) 2022-10-07 2025-10-28 アンブレツクス・インコーポレイテツド 薬物リンカー及びその抗体コンジュゲート
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
DE69936351T2 (de) 1998-10-30 2008-02-21 Novozymes A/S Glykosylierte proteine mit reduzierter allergenität
CA2367787C (en) 1999-04-28 2011-07-26 Alan P. Kozikowski Ligands for metabotropic glutamate receptors
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
AU2003240482B2 (en) 2002-05-30 2009-03-12 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
DK1812031T3 (en) 2004-11-01 2015-09-14 Univ California Compositions and methods for the modification of biomolecules
EP1828224B1 (en) 2004-12-22 2016-04-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
JP5773382B2 (ja) 2010-12-29 2015-09-02 株式会社Sumco シリカガラスルツボ及びその製造方法
KR102356286B1 (ko) 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
SG11201408494UA (en) 2012-06-19 2015-02-27 Ambrx Inc Anti-cd70 antibody drug conjugates
CN105283201B (zh) 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
CN108368172B (zh) * 2015-07-15 2022-06-14 根马布股份公司 人源化或嵌合cd3抗体
US11851488B2 (en) 2015-11-03 2023-12-26 Ambrx, Inc. Anti-CD3-folate conjugates and their uses
AU2017213886B2 (en) * 2016-02-04 2024-03-07 The California Institute For Biomedical Research Humanized anti-CD3 antibodies, conjugates and uses thereof

Similar Documents

Publication Publication Date Title
JP2021535140A5 (https=)
JP2024123231A5 (https=)
TWI250988B (en) Thrombopoietic compounds
US6177404B1 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
IL323631A (en) Compositions containing, methods and uses of antibody-TLR agonist conjugates
US6391305B1 (en) Conjugates useful in the treatment of prostate cancer
IL317851A (en) IL-15 conjugates and their use
CN108066772B (zh) 靶向tacstd2的抗体与药物偶联体(adc)分子
CN110698565A (zh) 靶向肿瘤的CD38-pHLIP融合肽
JP2012116864A (ja) Glp−1化合物
JP2002543111A (ja) ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅
CN115175917A (zh) 药物缀合物及其应用
Pechar et al. Coiled coil peptides as universal linkers for the attachment of recombinant proteins to polymer therapeutics
SK57399A3 (en) Conjugates useful in the treatment of prostate cancer
CN107206103A (zh) 用于治疗目的的抗体‑脲酶缀合物
CN115916801A (zh) 新型的α螺旋双性细胞穿透肽及其用途
US20030232760A1 (en) Conjugates useful in the treatment of prostate cancer
JPWO2020047176A5 (https=)
CN109414509B (zh) 使用双特异性抗体的抗体药物偶联物平台
JP6656661B2 (ja) プレキシンの結合調節剤
CN105524139A (zh) 高活性的肿瘤抑制剂及其制法和应用
CN115697375A (zh) 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
US10526385B2 (en) YAP protein inhibiting polypeptide and application thereof
WO2014044793A2 (en) Cd22-binding peptides
US20210214399A1 (en) Ph low insertion peptide and composition thereof